# A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

> **NCT04440059** · PHASE2 · COMPLETED · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia Recurrent
- Waldenstrom's Macroglobulinemia Refractory

## Interventions

- **DRUG:** ICP-022

## Key facts

- **NCT ID:** NCT04440059
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-10
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440059, "A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04440059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*